

2
Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 47519

Manuscript Type: REVIEW

Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma

Akateh C *et al.* Management strategies for hepatocellular carcinoma

Clifford Akateh, Sylvester M Black, Lanla Conteh, Eric D Miller, Anne Noonan, Eric Elliott, Timothy M Pawlik, Allan Tsung, Jordan M Cloyd

Abstract

9
Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a major cause of cancer-related mortality for which liver resection is an important curative-intent treatment option. However, many patients present with advanced disease and with underlying chronic liver disease and/or cirrhosis, limiting the proportion of patients who are surgical candidates. In addition, the development of recurrent or *de novo* cancers following surgical resection is common. These issues have led investigators to evaluate the benefit of neoadjuvant and adjuvant treatment strategies aimed at improving resectability rates and decreasing recurrence rates. While high-level evidence to guide treatment decision making is lacking, recent advances in locoregional and systemic therapies, including antiviral treatment and immunotherapy, raise the prospect of novel approaches that may improve the outcomes of patients with HCC. In this review, we evaluate the evidence for various neoadjuvant and adjuvant

Match Overview

1	Crossref 33 words Clifford Akateh, Timothy M. Pawlik, Jordan M. Cloyd. "Adjuvant antiviral therapy for the prevention of hepatocellular ca	1%
2	Internet 29 words crawled on 02-Apr-2019 f6publishing.blob.core.windows.net	1%
3	Internet 18 words crawled on 04-May-2019 www.jpabs.org	<1%
4	Internet 15 words crawled on 20-Sep-2017 www.anzctr.org.au	<1%
5	Internet 14 words crawled on 08-Apr-2018 legacy.impactjournals.com	<1%
6	Internet 13 words www.ncbi.nlm.nih.gov	<1%
7	Internet 12 words crawled on 18-Nov-2017 doaj.org	<1%
8	Internet 12 words crawled on 17-Mar-2019 liverdiseasenews.com	<1%
9	Internet 12 words crawled on 21-Mar-2019 lupinepublishers.com	<1%



Neoadjuvant and Adjuvant Treatment Strategies for Hepatocellular Carcinoma



登录

全部

图片

新闻

视频

购物

更多

设置

工具

找到约 620,000 条结果 (用时 0.43 秒)

Google 学术: Neoadjuvant and Adjuvant Treatment Strategies for Hepatocellular Carcinoma

... **hepatocellular carcinoma** before liver transplantation - Chapman - 被引用次数: 276

Treatment of colorectal liver metastases - Geoghegan - 被引用次数: 298

... in liver transplantation for **hepatocellular carcinoma** - Söderdahl - 被引用次数: 73

Management of potentially resectable hepatocellular carcinoma ...

<https://www.uptodate.com/.../management-of-potentially-resectable-hepatoce...> ▼ 翻译此页

作者: SA Curley - 相关文章

2018年10月26日 - **Hepatocellular carcinoma** (HCC) is an aggressive tumor that often ... to develop **neoadjuvant and adjuvant** systemic **therapy approaches** to ...

Neoadjuvant and adjuvant therapy for surgical resection of ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/19160192> ▼ 翻译此页

作者: M Samuel - 2009 - 被引用次数: 140 - 相关文章

2009年1月21日 - **Neoadjuvant and adjuvant therapy** for surgical resection of ... BACKGROUND: **Hepatocellular carcinoma** is a disease of great concern. ... SEARCH **STRATEGY**: We searched The Cochrane Hepato-Biliary Group Controlled ...

Neoadjuvant and adjuvant therapies for resectable hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pubmed/12013692> - 翻译此页

作者: S Wildi - 2002 - 被引用次数: 6 - 相关文章

Neoadjuvant and adjuvant therapies for resectable **hepatocellular carcinoma** (HCC) ... This paper summarizes the current **strategies** in the **treatment** of HCC.

Neoadjuvant Therapy for Hepatocellular Carcinoma: Is There An ...

<https://www.cancernetwork.com/.../neoadjuvant-therapy-hepatocellular-carci...> ▼ 翻译此页

作者: K Almhanna - 2007 - 被引用次数: 11 - 相关文章

Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the ... locoregional



All

Images

Videos

翻译成中文

关闭取词

117,000 Results

Any time ▼

What Is the Role of Adjuvant Therapy After Liver ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417809>

Sorafenib is currently being tested in the **adjuvant** setting after the resection or radiofrequency ablation of HCC in a multicenter phase 3 study [Sorafenib as **Adjuvant Treatment** in the Prevention of Recurrence of **Hepatocellular Carcinoma** (STORM)]. Data about the use of ...

Cited by: 9

Author: Christophe Duvoux, Tetsuya Kiuchi, Bern...

Publish Year: 2011

Neoadjuvant and adjuvant therapy for surgical resection of ...

onlinelibrary.wiley.com/doi/10.1002/14651858.CD001199.pub2/abstract

Neoadjuvant and **adjuvant** therapy for surgical resection of **hepatocellular carcinoma**. Miny Samuel, Pierce K-H Chow, Edwin Chan Shih-Yen, David Machin, Khee-Chee Soo. Article first published online: 21 Jan 2009 | DOI: 10.1002/14651858.CD001199.pub2. Version 1. **Neoadjuvant** and **adjuvant** therapy for operable **hepatocellular carcinoma**

Published in: [Cochrane Database of Systematic Reviews](#) · 2009

Authors: [Miny Samuel](#) · [Pierce K H Chow](#) · [Edwin Chan Shihyen](#) · [David Machin](#) · [Khee Chee Soo](#)

Affiliation: [Rti International](#) · [Singapore General Hospital](#) · [Cochrane Collaboration](#)

About: [Neoadjuvant therapy](#) · [Immunotherapy](#)


Neoadjuvant Therapy for Hepatocellular Carcinoma: Is There ...

<https://www.cancernetwork.com/oncology-journal/neoadjuvant-therapy-hepatocellular...> ▼

Aug 01, 2007 · **Hepatocellular carcinoma** (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. The incidence of **hepatocellular carcinoma** is increasing in the United States and worldwide. **Chronic liver disease and cirrhosis** (CLD) is a leading cause of death and disability.

Hepatocellular carcinoma

Medical Condition




The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

 Rare (Fewer than 200,000 cases per year in US)

 May be preventable by vaccine

 Diagnosis often requires lab test or imaging

 Treatment from medical professional advised

 Can last several months or years



Neoadjuvant and adjuvant treatment strategies continue to be studied in an attempt to broaden the pool of potential candidates. The Medicare national **coverage** policy for liver transplantation for cancers was recently expanded to include coverage for **hepatocellular carcinoma**.

[Liver Transplantation for Patients with Hepatobiliary ...](#)

www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id11TA.pdf

Is this answer helpful?

UpToDate

<https://www.uptodate.com/contents/management-of-potentially-resectable-hepatocellular...>

Samuel M, Chow PK, Chan Shih-Yen E, et al. **Neoadjuvant and adjuvant** therapy for surgical resection of **hepatocellular carcinoma**. Cochrane Database Syst Rev 2009; :CD001199. Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the **treatment** of **hepatocellular carcinoma**.

Neoadjuvant Therapy for Hepatocellular Carcinoma: Is There ...

<https://www.cancernetwork.com/oncology-journal/neoadjuvant-therapy-hepatocellular...>

Aug 01, 2007 · **Hepatocellular carcinoma** (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. The incidence of **hepatocellular carcinoma** is increasing in the United States and worldwide. Orthotopic liver transplantation (OLT) is a viable and potentially curative option for selected patients with HCC. Locoregional therapy has been used to control

Cited by: 7

Author: Khaldoun Almhanna, Sujith Kalmadi, Rob...

Publish Year: 2007

Adjuvant Versus Neoadjuvant Therapy in NSCLC - onclive.com


<https://www.onclive.com/.../adjuvant-versus-neoadjuvant-therapy-in-nsclc>

Corey J. Langer, MD, FACP: How long would you be willing to wait to do the surgery? Karen Kelly, MD: In the Cooperative Group SWOG trial, we waited for 2 to 3 cycles. So, there's precedence for ...

Hepatocellular carcinoma

Medical Condition

A common type of cancer affecting liver



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

Rare (Fewer than 200,000 cases per year in US)

May be preventable by vaccine

Diagnosis often requires lab test or imaging

Treatment from medical professional advised

Can last several months or years

Caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. Characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy, target drug delivery and use of radiation to kill the cancerous cells.

Symptoms

The early stages of the disease do not present any symptoms but in the later stages the symptoms which are noted are as follows: